Nosocomial blood-stream infections from extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumonia from GB Pant Hospital, New Delhi

Journal of Infection in Developing Countries

Volumn 4, Issue 8, 2010, Pages 517-520

  Taneja, Juhi ^a   Mishra, Bibhabati ^a   Thakur, Archana ^a   Dogra, Vinita ^a   Loomba, Poonam ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

Bacteremia; Extended spectrum beta lactamase; Nosocomial

Indexed keywords

AMIKACIN; CARBAPENEM DERIVATIVE; CEFOTAXIME; CLAVULANIC ACID; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TIGECYCLINE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BLOOD SAMPLING; BLOODSTREAM INFECTION; CONTROLLED STUDY; ESCHERICHIA COLI; HOSPITAL INFECTION; HUMAN; INDIA; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; PREVALENCE; SEPTICEMIA;

ESCHERICHIA COLI; KLEBSIELLA; KLEBSIELLA PNEUMONIAE;

EID: 78649308013     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.668     Document Type: Article

References (13)

1. Behera B, Mathur P, Das A, Kapil A (2009) Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India. Singapore Med J 50: 628-632.
2. Paterson DL, Bonomo RA (2005) Extended-spectrum ß-lactamases: a clinical update. Clin Microbiol Rev 18: 657-686.
3. Russell, JA (2006) Management of sepsis. N Engl J Med 355: 1699-1713.
4. Collee JG, Fraser AG, Marmion BP, Simmons A (1996) In: Mackie and McCartney Practical Medical Microbiology, 14th ed. Churchill Livingstone, London. pp. 385-404.
5. Clinical and Laboratory Standards Institute (2008) Performance standards for antimicrobial susceptibility testing, 18th informational supplement. CLSI document no. M100-S18.
6. Kapoor, H, Sumathi, M, Aggarwal P, Jain, SD, Kaur, J (2000) Spectrum of bacterial isolates in high risk areas of a tertiary care hospital: 3 year study. Indian J Med Microbiol 18: 166-169.
7. Jain A, Roy I, Gupta MK, Kumar M, Agarwal SK (2003) Prevalence of extended spectrum beta-lactamase producing Gram-negative bacteria in septicaemic neonates in a tertiary care hospital. J Med Microbiol 52: 421-5.
8. Goyal, A, Prasad KN, Prasad A, Gupta S, Ghoshal U, Ayyagari A (2009) Extended spectrum β-lactamases in Escherichia coli & Klebsiella pneumoniae & associated risk factors. Indian J Med Res 129: 695-700.
9. Gupta E, Mohanty S, Sood S, Dhawan B, Das BK, Kapil A. (2006) Emerging resistance to carbapenems in a tertiary care hospital in north India. Indian J Med Res 124(1): 95-98.
10. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME (2008) Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62: 895-904.
11. Jamal WY, Al Hashem G, Khodakhast F, Rotimi VO (2009) Comparative in vitro activity of tigecycline and nine other antibiotics against Gram-negative bacterial isolates, including ESBL-producing strains. J Chemother 21: 261-266.
12. Winokur PL, Canton R, Casellas JM, Legakis N (2001) Variations in the prevalence of strains expressing an extending-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 32 Supp 2: S94-103.
13. Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G; Italian ESBL Study Group (2002) Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs. Antimicrob Agents Chemother 46: 196-202.